107 related articles for article (PubMed ID: 3049819)
1. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide.
Campbell MJ; Esserman L; Levy R
J Immunol; 1988 Nov; 141(9):3227-33. PubMed ID: 3049819
[TBL] [Abstract][Full Text] [Related]
2. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action.
Basham TY; Race ER; Campbell MJ; Reid TR; Levy R; Merigan TC
J Immunol; 1988 Oct; 141(8):2855-60. PubMed ID: 2971732
[TBL] [Abstract][Full Text] [Related]
4. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.
Kaminski MS; Kitamura K; Maloney DG; Levy R
J Immunol; 1987 Feb; 138(4):1289-96. PubMed ID: 3492546
[TBL] [Abstract][Full Text] [Related]
5. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of tumor in mice in combination with cyclophosphamide.
Sarna S; Bhola RK
Arch Immunol Ther Exp (Warsz); 1989; 37(5-6):533-8. PubMed ID: 2487364
[TBL] [Abstract][Full Text] [Related]
7. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants.
Starnes CO; Carroll WL; Campbell MJ; Houston LL; Apell G; Levy R
J Immunol; 1988 Jul; 141(1):333-9. PubMed ID: 3132505
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
11. Idiotypic vaccination as a treatment for a B cell lymphoma.
George AJ; Folkard SG; Hamblin TJ; Stevenson FK
J Immunol; 1988 Sep; 141(6):2168-74. PubMed ID: 3049800
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
13. Antigen-induced murine B-cell lymphomas. III. Passive anti-idiotype serum therapy and its combined effect with chemotherapy.
Lanier LL; Babcock GF; Lynes MA; Haughton G
J Natl Cancer Inst; 1979 Dec; 63(6):1417-22. PubMed ID: 316036
[No Abstract] [Full Text] [Related]
14. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
[TBL] [Abstract][Full Text] [Related]
15. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
16. Chemoimmunotherapy of B 16 melanoma and P388 leukemia with cyclophosphamide and pyrimidinones.
Li LH; Johnson MA; Moeller RB; Wallace TL
Cancer Res; 1984 Jul; 44(7):2841-7. PubMed ID: 6722813
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
Kedar E; Chriqui-Zeira E; Kyriazis AP
J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
[TBL] [Abstract][Full Text] [Related]
18. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
Nitta K; Tanaka T; Takeuchi M
Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
[TBL] [Abstract][Full Text] [Related]
19. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
20. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
